The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care

doi:10.1186/1471-2431-12-78

From:

BMC Pediatr. 2012; 12: 78.

Published online 2012 June 19. doi: 10.1186/1471-2431-12-78

Copyright/LicenseRequest permission to reuse: Copyright ©2012 McCarthy et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

An external file that holds a picture, illustration, etc.
Object name is 1471-2431-12-78-1.jpg Object name is 1471-2431-12-78-1.jpg

Figure 1

Prevalence of pharmacologically treated attention deficit hyperactivity disorder (methylphenidate, dexamfetamine or atomoxetine) in patients aged 6-years and over in UK general practice (with 95% confidence intervals).

Articles from BMC Pediatrics are provided here courtesy of
BioMed Central